Certara (CERT) Q2 Revenue Jumps 12%

Certara (NASDAQ:CERT), a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue beat, with reported GAAP revenue of $104.6 million, exceeding analyst expectations, but non-GAAP earnings per share (EPS) missed consensus by $0.03. The company delivered double-digit top-line growth, driven primarily by its software segment, but the bottom line continues to face pressure. GAAP net losses narrowed sharply year over year. Overall, the quarter was marked by continued software momentum but mixed progress on translating growth into profit. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Certara operates at the intersection of life sciences and software technology. Its main products are biosimulation platforms, which help pharmaceutical companies simulate how drugs interact within the body using computer models. This approach helps reduce the time, cost, and risk of drug development.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool